** Shares of drugmaker MannKind MNKD.O rise 5.1% to $3.82

** Co says the U.S. FDA approved expanded use of its inhaled insulin Afrezza for children and adolescents aged 6 and older with type 1 or type 2 diabetes

** Afrezza is taken through a small inhaler, offering patients under 18 years of age a needle-free treatment option

** Co says eligible patients can get access to Afrezza for $35 or less a month

** Including session's move, MNKD down 32.5% YTD